TMCnet News
Research and Markets: TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/cm2s97/tnfalpha) has announced the addition of the "TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering. The TNF-alpha signaling pathway stimulates the MAPK signaling module and activates NFkB. There are today 359 companies plus partners developing 531 TNF-alpha pathway targeting drugs in 1960 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 250 drugs. TNF-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 247 different targets. All included targets have been ross-referenced for the presence of mutations associated with human cancer. To date 243 out of the 245 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 54 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Drug Pipeline Update at a Glance Investigators
Drug name & Synonyms
Developmental stage
Indications
Pipeline Breakdown According to Number of Drugs
For more information visit http://www.researchandmarkets.com/research/cm2s97/tnfalpha.
|